Skip to content
MedsAcross

Medicine

Cardene IV 20 mg/200 mL injection

Nicardipine · Intravenous · Baxter Healthcare
Available on requestPrescription onlyUS FDA

Cardene IV 20 mg/200 mL injection is a prescription medicine containing Nicardipine for intravenous use, marketed by Baxter Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Protect from freezing. Store at controlled room temperature 20º to 25ºC (68º…

Key facts

Active ingredient (INN)
Nicardipine
Brand
Cardene IV
Strength
20 mg/200 mL
Dosage form
Injection
Route
Intravenous
Packs
10 bags of 200 mL
Marketing authorisation holder
Baxter Healthcare
Manufacturer
Baxter Healthcare
Origin register
US FDA, United States
Storage
Protect from freezing. Store at controlled room temperature 20º to 25ºC (68º to 77ºF), refer to USP Controlled Room Temperature. Protect from light, store in carton until ready to use.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
C08CA04 Nicardipine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 January 1992
Identifiers
RxCUI 858599, 858601, 858603 +1DailyMed set ID f12cea0d-b7cd-41d8-b551-2c74cc7f5f4e, 5499cfac-9147-4d5d-a8cb-f8d64f1481af, a3e33add-0d09-423a-9109-42e5ba7148d5NDC 43066-009, 43066-021, 43066-026Application NDA019734

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
10 bag in 1 carton / 200 mL in 1 bag43066-009-10Baxter Healthcare11 January 2021
10 bag in 1 carton / 200 mL in 1 bag43066-021-10Baxter Healthcare22 August 2020
10 bag in 1 carton / 200 mL in 1 bag43066-026-10Baxter Healthcare22 August 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 21 December 1988Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Nicardipine 20 mg/200 mL injection.

Compare 1

Other strengths and forms of Nicardipine

Clinical summary

Nicardipine is a dihydropyridine calcium channel blocker indicated for the short-term treatment of hypertension in adults when oral therapy is not feasible. It is available as injection and capsules for intravenous and oral use. MedsAcross supplies Nicardipine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Nicardipine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Cardene IV 20 mg/200 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.